Liquidia (LQDA) Financials: History & Chart

Liquidia Corporation(LQDA)

Medical - Pharmaceuticals · Morrisville, NC

$26.71-0.93 (-3.38%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

About Liquidia Corporation

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Morrisville, NC

216 employees

www.liquidia.com

Healthcare / Medical - Pharmaceuticals

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO: Roger A. Jeffs

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	450.91M	171.68M	132.87M	92.02M	54.34M	8.84M	3.12M	2.92M	4.45M
Cost of Goods Sold	33.93M	11.55M	12.15M	7.05M	3.17M	1.29M	1.52M	1.35M	1.56M
Gross Profit	416.98M	160.13M	120.72M	84.97M	51.17M	7.54M	1.60M	1.56M	2.88M
Gross Profit Margin	92.5%	93.3%	90.9%	92.3%	94.2%	85.4%	51.4%	53.6%	64.8%
Total Operating Expenses	248.41M	74.61M	59.21M	65.18M	49.40M	45.05M	37.03M	37.67M	32.07M
Research & Development	55.75M	17.18M	12.27M	16.94M	9.35M	6.02M	6.97M	16.48M	11.89M
Selling, General & Administrative	192.66M	57.43M	46.94M	48.24M	40.06M	38.82M	30.06M	21.20M	20.18M
Operating Income (EBIT)	168.57M	85.52M	61.50M	19.79M	1.77M	-37.51M	-35.42M	-36.11M	-29.19M
Operating Margin	37.4%	49.8%	46.3%	21.5%	3.3%	-424.4%	-1135.4%	-1237.8%	-656.2%
Income Before Tax (EBT)	149.50M	81.70M	56.78M	14.55M	-3.53M	-41.58M	-38.37M	-38.37M	-23.16M
Interest Income	7.56M	2.48M	1.77M	1.67M	1.65M	1.58M	1.73M	2.10M	1.81M
Interest Expense	26.63M	6.30M	6.49M	6.90M	6.95M	5.66M	4.67M	4.37M	3.00M
Other Income/Expense	-19.07M	-3.82M	-4.72M	-5.23M	-5.30M	-4.07M	-2.94M	-2.26M	6.03M
Net Income	138.61M	74.72M	52.86M	14.55M	-3.53M	-41.58M	-38.37M	-38.37M	-23.16M
Income Tax Expense	10.89M	6.97M	3.92M	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	30.7%	43.5%	39.8%	15.8%	-6.5%	-470.5%	-1229.7%	-1315.4%	-520.6%
EBITDA	170.27M	85.92M	62.00M	20.11M	2.24M	-37.22M	-34.97M	-35.59M	-28.58M
EBITDA Margin	37.8%	50.0%	46.7%	21.9%	4.1%	-421.2%	-1121.0%	-1220.1%	-642.5%
Depreciation & Amortization	1.69M	400K	497K	320K	476K	281K	451K	518K	610K
EPS Basic	1.57	0.84	0.60	0.17	-0.04	-0.49	-0.45	-0.45	-0.30
EPS Diluted	1.37	0.74	0.52	0.15	-0.04	-0.49	-0.45	-0.45	-0.30
Weighted Average Basic Shares	88.89M	88.89M	88.01M	87.11M	86.33M	85.59M	85.17M	84.68M	78.32M
Weighted Average Diluted Shares	101.40M	101.40M	101.11M	100.05M	86.33M	85.59M	85.17M	84.68M	78.32M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	158.32M	14.00M	17.49M	15.94M	12.85M	740K	8.07M	2.71M
Cost of Goods Sold	13.24M	5.88M	2.89M	2.86M	3.02M	238K	807K	121K
Gross Profit	145.08M	8.12M	14.60M	13.08M	9.83M	502K	7.26M	2.59M
Gross Profit Margin	91.6%	58.0%	83.5%	82.1%	76.5%	67.9%	90.0%	95.5%
Total Operating Expenses	196.45M	129.41M	87.98M	51.85M	43.63M	59.59M	54.09M	37.45M
Research & Development	39.28M	47.84M	43.24M	19.43M	20.52M	32.22M	40.49M	28.70M
Selling, General & Administrative	157.18M	81.57M	44.74M	32.41M	23.11M	27.37M	13.60M	8.75M
Operating Income (EBIT)	-51.38M	-121.29M	-73.38M	-38.77M	-33.80M	-59.09M	-46.82M	-34.87M
Operating Margin	-32.5%	-866.6%	-419.6%	-243.3%	-263.0%	-7989.0%	-580.1%	-1288.1%
Income Before Tax (EBT)	-68.92M	-130.39M	-78.50M	-41.02M	-34.58M	-59.76M	-47.58M	-53.14M
Interest Income	6.62M	7.65M	3.47M	1.09M	33K	184K	614K	305K
Interest Expense	24.17M	12.49M	6.27M	2.34M	762K	858K	1.37M	18.99M
Other Income/Expense	-17.55M	-9.10M	-5.12M	-2.25M	-782K	-674K	-760K	-18.27M
Net Income	-68.92M	-130.39M	-78.50M	-41.02M	-34.58M	-59.76M	-47.58M	-53.14M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-43.5%	-931.7%	-448.9%	-257.4%	-269.0%	-8080.1%	-589.5%	-1962.9%
EBITDA	-49.85M	-119.10M	-71.21M	-35.12M	-28.18M	-55.97M	-44.03M	-33.32M
EBITDA Margin	-31.5%	-850.9%	-407.2%	-220.4%	-219.3%	-7567.7%	-545.5%	-1231.1%
Depreciation & Amortization	1.53M	2.20M	2.18M	3.65M	5.61M	3.12M	2.79M	1.54M
EPS Basic	-0.80	-1.66	-1.21	-0.67	-0.70	-1.76	-2.51	-7.42
EPS Diluted	-0.80	-1.66	-1.21	-0.67	-0.70	-1.76	-2.51	-7.42
Weighted Average Basic Shares	86.06M	78.71M	64.99M	60.96M	49.68M	33.89M	18.48M	7.16M
Weighted Average Diluted Shares	86.06M	78.71M	64.99M	60.96M	49.68M	33.89M	18.48M	7.16M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.